期刊
JOURNAL OF NUCLEAR MEDICINE
卷 57, 期 8, 页码 1207-1213出版社
SOC NUCLEAR MEDICINE INC
DOI: 10.2967/jnumed.115.169532
关键词
neuroendocrine; F-18-fluroethyl [Tyr(3)] octreotate analog; PET/CT imaging
资金
- U.K. Medical Research Council [MR/J007986/1]
- Experimental Cancer Medicine Centres [C37/A7283]
- National Institute for Health Research (NIHR) Biomedical Research Centre
- Imperial College London
- MRC [MR/J007986/1, MR/N020782/1] Funding Source: UKRI
- Cancer Research UK [16584, 10337, 12011] Funding Source: researchfish
- Medical Research Council [MR/J007986/1, MR/N020782/1] Funding Source: researchfish
- National Institute for Health Research [NIHR/CS/009/009] Funding Source: researchfish
We conducted the first-in-human study of F-18-fluoroethyl triazole [Tyr(3)] octreotate (F-18-FET-beta AG-TOCA) in patients with neuroendocrine tumors (NETs) to evaluate biodistribution, dosimetry, and safety. Despite advances in clinical imaging, detection and quantification of NET activity remains a challenge, with no universally accepted imaging standard. Methods: Nine patients were enrolled. Eight patients had sporadic NETs, and 1 had multiple endocrine neoplasia type 1 syndrome. Patients received 137-163 MBq (mean +/- SD, 155.7 +/- 8 MBq) of F-18-FET-beta AG-TOCA. Safety data were obtained during and 24 h after radioligand administration. Patients underwent detailed whole-body PET/CT multibed scanning over 4 h with sampling of venous bloods for radioactivity and radioactive metabolite quantification. Regions of interest were defined to derive individual and mean organ residence times; effective dose was calculated with OLINDA 1.1. Results: All patients tolerated F-18-FET-beta AG-TOCA with no adverse events. Over 60% parent radioligand was present in plasma at 60 min. High tumor (primary and metastases)-to-background contrast images were observed. Physiologic distribution was seen in the pituitary, salivary glands, thyroid, and spleen, with low background distribution in the liver, an organ in which metastases commonly occur. The organs receiving highest absorbed dose were the gallbladder, spleen, stomach, liver, kidneys, and bladder. The calculated effective dose over all subjects (mean +/- SD) was 0.029 +/- 0.004 mSv/MBq. Conclusion: The favorable safety, imaging, and dosimetric profile makes F-18-FET-beta AG-TOCA a promising candidate radioligand for staging and management of NETs. Clinical studies in an expanded cohort are ongoing to clinically qualify this agent.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据